These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 600960)

  • 21. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
    Chalmers TM; Davie MW; Hunter JO; Szaz KF
    J Urol Nephrol (Paris); 1974 Dec; 80(12):981. PubMed ID: 4617778
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term treatment of uraemic osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1976; 12():221-6. PubMed ID: 935114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Nephron; 1976; 16(5):359-70. PubMed ID: 1264309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
    Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1alpha-Hydroxycholecalciferol in children with renal osteodystrophy.
    Postlethwaite RJ; Houston IB
    Calcif Tissue Res; 1977 May; 22 Suppl():371-5. PubMed ID: 912549
    [No Abstract]   [Full Text] [Related]  

  • 29. The investigation and treatment of renal bone disease.
    Catto GR; MacLeod M
    Am J Med; 1976 Jul; 61(1):64-73. PubMed ID: 937372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effect of 1alpha-hydroxycholecalciferol in children and adults with renal glomerular osteodystrophy.
    Henderson RG; Kanis JA; Ledingham JG; Oliver DO; Russel RG; Smith R; Walton RJ
    Calcif Tissue Res; 1976 Aug; 21 Suppl():221-5. PubMed ID: 782661
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of renal osteodystrophy].
    Duursma SA; Dorhout Mees EJ
    Ned Tijdschr Geneeskd; 1978 Mar; 122(11):373-8. PubMed ID: 634388
    [No Abstract]   [Full Text] [Related]  

  • 32. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
    Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
    Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy].
    Minatoguchi T
    Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical picture, diagnosis and therapy of renal osteodystrophy].
    Bombor H
    Z Urol Nephrol; 1977 Aug; 70(8):603-7. PubMed ID: 335702
    [No Abstract]   [Full Text] [Related]  

  • 38. Calcifediol in chronic renal insufficiency. Skeletal response.
    Teitelbaum SL; Bone JM; Stein PM; Gilden JJ; Bates M; Boisseau VC; Avioli LV
    JAMA; 1976 Jan; 235(2):164-7. PubMed ID: 946022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
    Marco Franco JE; Alarcón Zurita A; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Dalmau Diana M
    Rev Clin Esp; 1982 Jan; 164(1):33-5. PubMed ID: 7071401
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment of renal osteopathy with 5,6-trans-25-hydroxycholecalciferol (author's transl)].
    Kraft D; Schaefer K; Grigoleit HG; Offermann G; von Herrath D; Delling G
    Dtsch Med Wochenschr; 1979 Nov; 104(48):1706-10. PubMed ID: 520165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.